Liraglutide relieves cardiac dilated function than DPP-4 inhibitors

Area of Science:

• Cardiology
• Endocrinology
• Nephrology

Background:

• Diabetes mellitus is a progressive condition linked to cardiovascular complications.
• Patients with type 2 diabetes and renal impairment are at increased risk.
• Evaluating novel treatments for managing cardiac function in this population is crucial.

Purpose of the Study:

• To compare the effects of liraglutide, sitagliptin, and linagliptin on cardiac function.
• To assess the impact of these antidiabetic agents on renal function markers.
• To determine the efficacy of these drugs in improving cardiovascular parameters in patients with type 2 diabetes and renal impairment.

Main Methods:

• A randomized trial involving 139 patients with type 2 diabetes and renal impairment.
• Patients received liraglutide, sitagliptin, or linagliptin for 48 months.
• Regular monitoring of glycemic control, renal function, and cardiac function via echocardiography.

Main Results:

• All groups showed significant reductions in glucose and blood pressure.
• Liraglutide demonstrated a sustained decrease in albuminuria compared to sitagliptin and linagliptin.
• Only liraglutide significantly improved cardiac diastolic function (E/e', left atrial dimension).

Conclusions:

• Liraglutide effectively controlled glucose and blood pressure, reduced albuminuria, and improved diastolic function.
• Sitagliptin and linagliptin did not show improvements in diastolic function.
• Liraglutide may offer superior cardiovascular benefits in type 2 diabetes patients with renal impairment.